Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.Methods: The sitagliptin cohort included 1,578 patients aged 20 years and above. The nonsitagli...

Full description

Bibliographic Details
Main Authors:	Shih-Yi Lin, Wu-Huei Hsu, Cheng-Chieh Lin, Cheng-Li Lin, Chun-Hao Tsai, Hung-Chieh Yeh, Chung-Y. Hsu, Chia-Hung Kao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-06-01
Series:	Frontiers in Pharmacology
Subjects:	fracture sitagliptin dipeptidyl peptidase-4 inhibitor cohort study diabetes
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2018.00677/full

Similar Items

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

Noncardiac pulmonary edema induced by sitagliptin treatment
by: Tahir Belice, et al.
Published: (2014-01-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01)

Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures
by: Dong-Hou Kim, et al.
Published: (2012-04-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01)

The durability of sitagliptin in elderly patients with type 2 diabetes
by: Hsieh CJ, et al.
Published: (2014-11-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
by: Yuya Tsurutani, MD, PhD, et al.
Published: (2017-01-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats
by: Aly M. Abdelrahman, et al.
Published: (2019-02-01)

Association of Transfusion With Risks of Dementia or Alzheimer’s Disease: A Population-Based Cohort Study
by: Shih-Yi Lin, et al.
Published: (2019-08-01)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
by: Masato Furuhashi, et al.
Published: (2020-06-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Association of Arrhythmia in Patients with Cervical Spondylosis: A Nationwide Population-Based Cohort Study
by: Shih-Yi Lin, et al.
Published: (2018-08-01)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
by: Yi-Hsuan Lin, et al.
Published: (2018-10-01)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
by: Soon Ae Kim, et al.
Published: (2011-04-01)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
by: Chintan Shah, et al.
Published: (2020-03-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum
by: Carmen Lammi, et al.
Published: (2018-08-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Association of Depression and Cervical Spondylosis: A Nationwide Retrospective Propensity Score-Matched Cohort Study
by: Shih-Yi Lin, et al.
Published: (2018-10-01)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
by: Xiao-jun Zhou, et al.
Published: (2019-03-01)

Effect of acute pancreatitis on the risk of developing osteoporosis: A nationwide cohort study.
by: Shih-Yi Lin, et al.
Published: (2017-01-01)

Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy
by: Chor Ho Jo, et al.
Published: (2018-06-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

Altered T‐cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase‐4 inhibitor: A 1‐year open‐label randomized controlled trial
by: Xia Wang, et al.
Published: (2019-03-01)

Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study
by: Shih-Yi Lin, et al.
Published: (2020-03-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

Risk of Urticaria in Children with Type 1 Diabetes Mellitus: A Nationwide Cohort Study
by: Shih-Yi Lin, et al.
Published: (2019-12-01)

Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study
by: Li-Min Sun, et al.
Published: (2019-06-01)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
by: Shih-Chieh Shao, et al.
Published: (2020-02-01)

Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study
by: Po-Chung Cheng, et al.
Published: (2019-10-01)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
by: Chia-Yu Chang, et al.
Published: (2017-12-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Risk and Predisposing Factors for Suicide Attempts in Patients with Migraine and Status Migrainosus: A Nationwide Population-Based Study
by: Tomor Harnod, et al.
Published: (2018-09-01)